Onyx Health Joins Forces with Rare Disease Specialists Actigen
April 14, 2022 | Communications, Marketing, New Business, healthcare
Onyx Health will be working with Actigen to raise awareness of their innovative clinical trial work in rare diseases and the need to develop new treatment solutions.
Healthcare marketing communications specialists, Onyx Health, have teamed up with Cambridge-based biotech company, Actigen, to promote their pioneering work in the field of rare diseases.
Actigen’s work focuses on identifying and developing biological medicines for rare diseases with unmet medical needs. The current focus of Actigen’s work is on the development of a drug for a potential breakthrough treatment for the life-limiting rare disease known as MPS II or Hunter Syndrome.
MPS II is a serious, rare disease that has a major impact on the physical and neurological health of those affected. If left untreated, it can cause progressive deterioration of patients’ internal organs and cognitive behavioural issues.
Like many rare diseases, MPS II lacks adequate treatment options, as the current therapies merely improve the functioning of patients’ internal organs without addressing the neurological issues.
Actigen’s forthcoming clinical trial work on GNR-055 presents an opportunity to find a superior treatment option for MPS II, which is designed to address the cognitive function and behaviour disruption, significantly enhancing patient’s quality of life.
Actigen’s Managing Director, Michael Braunagel, said, “MPS II is just one of the hundreds of rare diseases where modern medicine can lead to a massive improvement of the treatment options. At Actigen, our mission is to improve the lives of individuals with rare diseases, and we hope that GNR-055 will be the start of many more trials for orphan diseases”.
“Onyx Health’s communication support and specialist sector knowledge will help us receive greater recognition for our expertise in rare diseases. GNR-055 is the first therapeutic in our innovative development pipeline, and we hope to be seen and heard for the great work we do, with the help of Onyx Health”.
Onyx Health was approached by Actigen when they were looking for a communications agency with scientific knowledge and expertise in pharmaceuticals and life sciences. The Newcastle-based agency is providing Actigen with a variety of creative branding and communications work to showcase their expertise and establish a strong reputation in the biotech market.
Onyx Health’s Associate Director, Louise Flintoft, said, “Clinical trials for rare diseases are a vitally important aspect of clinical research, though often neglected. There are 6,000 rare diseases affecting approximately 300 million people worldwide; however, 95% of rare diseases have no effective treatment options”.
“We are looking forward to working with Actigen to highlight this serious issue and the need for greater clinical research into rare diseases. While the importance of research into rare diseases is becoming increasingly recognised with the recent publication of the Government’s Rare Disease Action plan, more needs to be done”.
This content was provided by Onyx Health
Company Details
Latest Content from Onyx Health
Onyx Health Announces Two Top Appointments
Onyx health have made two senior appointments to their communications team
Onyx Health Marks Record Growth with Six New Appointments
Onyx Health has expanded its communications team with six new appointments, after more than doubling its fee incomes and expanding its international client portfolio over the past year
Onyx Health Launch Creative Studio After Record Year
Healthcare marketing communications specialists Onyx Health have set up a new creative studio following a year of record income growth and international client expansion.
PulmoBioMed Wins National Life Science Competition
Newly launched Northumbria University spinout PulmoBioMed has been handpicked as the winners of Onyx Health's ThinkBig competition
Licensing Deal for NP213 Nail Fungus Treatment is Another Key Milestone for NovaBiotics
Leading biotechnology company NovaBiotics Ltd have secured a major licensing deal for their fungal nail treatment
Newcells Biotech secures over £5m for 3D tissue models
Newcells Biotech have received multi-million investment to develop their pioneering 3D tissue models
Onyx Health Targets Digital Growth with New Executive Director
Healthcare marketing communications agency Onyx Health have appointed Trevor Pill as their new Executive Director
Onyx Health Launch National Competition for Life Science SMEs
Healthcare marketing communications agency Onyx Health are launching a national competition #ThinkBig to help health and life sciences SMEs bounce back from the COVID-19 crisis
Onyx Health Celebrates Its 10th Anniversary with Five New Hires
Onyx Health have marked their 10th anniversary by welcoming five new members to their rapidly expanding team. These appointments come on the back of the agency’s continued growth throughout the...
Lifesaving QR Code Wearable Launched to Help Emergency Services
MedTech company Mavin Informatics have just launched mi-SOS, a lifesaving QR code-based medical identity wearable across the UK